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Summary Study objective: To investigate the frequency of respiratory bacterial
infections in hospitalized patients, admitted with an acute exacerbation of chronic
obstructive pulmonary disease (COPD), to identify the responsible pathogens by
sputum culture and to assess patient characteristics in relation to sputum culture
results. Methods:We prospectively evaluated clinical data and sputum culture results
of 171 patients, admitted to the pulmonology department of the University Hospital
Maastricht with an acute exacerbation of COPD from 1st January 1999 until 31st
December 1999. Results: Eighty-five patients (50%) had positive sputum cultures,
indicating the presence of bacterial infection. Pathogens most frequently isolated
were: Haemophilus influenzae (45%), Streptococcus pneumoniae (27%), and
Pseudomonas aeruginosa (15%). Patients with more severely compromised lung
function had a higher incidence of bacterial infections (P ¼ 0:026). There were no
significant differences in age, lung function parameters, blood gas results and length
of hospital stay between patients with and without bacterial infection. There were no
correlations between the type of bacteria isolated and clinical characteristics.
Conclusion: Incidence of bacterial infection during acute exacerbations of COPD is
about 50%. Patients with and without bacterial infection are not different in clinical
characteristics or in outcome parameters. Patients with lower FEV1 have a higher
incidence of bacterial infections, but there is no difference in the type of bacterial
infection. In the future, the pathogenic role of bacterial infection in exacerbations of
COPD should be further investigated, especially the role of bacterial infection in
relation to local and systemic inflammation.







Chronic obstructive pulmonary disease (COPD)
comprises a heterogeneous group of conditions,
characterized by varying degrees of expiratory flow
limitation. Exacerbations punctuate the clinical
course of COPD in many patients. These episodes
of acute exacerbation can vary considerably in
severity: part of the exacerbations will remain
unreported while some episodes require hospital
admission. Hospital admission for acute exacerba-
tions forms the major component of the economical
burden of COPD in western countries.1 These
exacerbations are characterized by varying combi-
nations of symptoms as increase in cough, sputum
production, worsening of dyspnea or changes in
sputum purulence.
Recent studies have indicated that health
status of patients with COPD has been influenced
by the presence and frequency of these acute
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exacerbations.2,3 The exact role of periods of acute
exacerbations in the pathogenesis of COPD remains
unclear, especially the relationship between bron-
chial inflammation and lung defense during these
possible noxious events.4 Some studies have in-
dicated that recurrent exacerbations may be
associated with increased airway inflammation,
although many factors may influence the state of
inflammation in the airways.5 Recent data also
suggest the presence of decreased antiproteinase
activity in sputum of patients with recurrent
exacerbations.4
Exacerbations are not only heterogeneous in
severity and symptom characteristics but are also
in nature. Although several events may lead to
acute exacerbations, respiratory tract infections
are often considered as the initiating event
contributing to the deterioration in the clinical
condition. Especially, the role of bacterial infec-
tions and the value of antibiotic therapy have been
a matter of debate for many decades.6–8
An important problem in defining the role of
bacteria in these episodes of acute exacerbation
is the bacterial colonization of the lower
airways even in the absence of symptoms of an
exacerbation.7 Careful investigations have re-
ported the presence of bacterial pathogens in only
about 50% of exacerbations.9–15 However, these
studies have been performed in different popula-
tions of COPD patients, and most frequently in
outpatients.
Recently, two studies have investigated the type
of bacterial pathogens isolated in sputum of COPD
patients, hospitalized for an acute exacerba-
tion.12,13 In these studies a correlation was found
between lung function and the type of bacteria
isolated: patients with more compromised lung
function had a higher incidence of infections with
Pseudomonas aeruginosa and other Gram-negative
bacteria isolated from their sputum. These findings
suggested that patients with more advanced lung
disease may need a different pharmacological
therapy than patients with milder disease.
The generalization of these findings as well as the
interpretation of them as disease-specific findings
are hampered by limited availability of data on
distribution of bacterial flora in COPD patients from
different geographical areas as qualitative differ-
ences in bacterial flora can be related to many
other factors. Therefore, it seems interesting to
investigate prospectively the prevalence of acute
bacterial infections during these episodes of hospi-
tal admission as well as if specific patient profiles
are related to a different pattern of microorgan-
isms in patients admitted for an acute exacerbation
of the disease.
Furthermore, we questioned if the presence of
bacterial infection influences the clinical outcome
of hospital admissions for acute exacerbations.
Material and methods
Study population and study design
All patients, admitted with an acute exacerbation
of COPD to the pulmonology ward of the University
Hospital Maastricht, between 1st January 1999 and
31st December 1999, were prospectively evalu-
ated. All patients were diagnosed as having COPD,
according to the criteria of the American Thoracic
Society.16 Acute exacerbation was defined by the
presence of an increase in at least two of the three
following symptoms: dyspnea, cough and sputum
purulence.
Admission to the hospital was deemed necessary
based on the clinical situation of the patient or the
presence of complicating factors as respiratory
failure. In all cases, the need for admission was
decided by a senior chest physician, experienced in
the management of COPD patients. Chest X-rays
were performed in each patient on admission and
patients with lobar infiltrates or radiologic signs of
pneumonia on chest X-ray were excluded from the
study.
Patients were included only once in the study
even if hospitalized more frequently. For all
included patients the following data were assessed:
medical history, lung function measurements,
blood gases, duration of hospital stay, previous
treatment, chronic corticosteroid use and results of
sputum cultures. Medical history, previous treat-
ment and use of corticosteroids were recorded
from the patients charts on standardized forms.
Chronic use of oral corticosteroids was defined as
the use of daily oral corticosteroids for at least 1
year in a dosage of at least 5mg Prednisolone or
equivalent. On admission, arterial blood gases at
rest were assessed by puncture of the radial artery
during room air breathing. Patients were dis-
charged from the pulmonary ward by decision of a
senior chest physician, unaware of the goals of the
present study. Total duration of hospital stay was
recorded, counting from the first day of admission
before 0.00 h until the day of discharge.
Patients were treated with a standard protocol
consisting of intravenous administration of corti-
costeroids and theophylline and nebulization of
salbutamol and ipratropiumbromide as bronchodi-
lating agents. O2 was titrated by follow-up of blood
gas values as well as continuous monitoring of
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oxygen saturation. Antibiotics were not prescribed
until the results of the sputum cultures were
available, unless the clinical condition of the
patient necessitated early intervention based on
documented resistance pattern of isolated micro-
organisms.
Lung function data
Spirometries were performed daily during admis-
sion for the exacerbation. Spirometries were
performed using the portable pneumotachograph
from Jaeger pulmonary function equipment (W-
.urzburg, Germany). The value after recovery, prior
to discharge from the hospital was used in the
analyses. Based on the ATS criteria,16 lung function
was rated in three stages of severity: stage I: FEV1
ofX50% predicted, stage II: FEV1 between 35% and
50% predicted, stage III: FEV1 p35% predicted.
Sputum cultures
At least one sample of spontaneously expectorated
sputum for microbiologic evaluation was obtained
in all patients during admission. This is part of a
common medical practice in our hospital for
patients admitted for an acute exacerbation, and
also it is recommend in the recently published
GOLD guidelines for the management of COPD.17
Samples were collected in sterile sputum cups and
sent to the laboratory within 1 h after expectora-
tion.
A Gram stain of the sputum in the area of
maximal purulence was examined for polymorpho-
nuclear leukocytes and epithelial cells. The number
of leukocytes was semiquantitatively described as:
none, sporadic, few, moderate or many. A sputum
sample was considered representative if many
leukocytes were present in the absence of epithe-
lial cells. Another portion of a documented puru-
lent material was used for microbiological analysis.
Sputa were processed according to standard micro-
biological methods.18 A sputum culture was con-
sidered as positive (proving bacterial infection) if
significant bacterial growth was present as defined
by the number of bacteria (higher than 105 colony
forming units¼ cfu) in a representative sample.
Identified bacteria were classified into three
groups: group 1 included Haemophilus influenzae
and Moraxella catarrhalis, group 2 included Strep-
tococcus pneumoniae and other Gram-positive
cocci and group 3 included Pseudomonas and other
Gram-negative microorganisms. Other identified
bacteria are considered non-pathogenic microor-
ganisms (NPMs), belonging to the oropharyngeal or
gastrointestinal flora.
A microbial resistance pattern was available for
all pathogens. For all pathogens resistance patterns
were determined for Amoxicillin, Amoxicillin/Cla-
vulanic acid, Doxycyclin and Co-trimoxazole. In
case of isolation of Pseudomonas and other Gram-
negative species resistance patterns to Gentamy-
cin, Piperacillin, Ciprofloxacine, Ofloxacine and
Cefuroxim were determined additionally.
Statistical analysis
The statistical analyses were performed using the
Statistical Products and Service Solutions (SPSS;
Chicago, IL, USA) for Windows Package. Groups
were compared by analysis of variance (ANOVA).
The w2 test was used to compare categorical




Between 1st January 1999 and 31st December 1999
171 patients were included with acute exacerba-
tion of COPD. Characteristics of the study popula-
tion are summarized in Table 1. Most patients were
elderly with severely impaired lung function (mean
FEV1 was 0.84 l or 34.6% predicted).
Hypoxia as well as hypercapnia were very
common findings on admission; 141 (¼ 85%) of the
patients had arterial oxygen tension o8.7 kPa,
arterial carbon dioxide tension higher than 5.9 kPa
was measured in 93 patients (¼ 55%).
Sixty-three patients (¼ 37%) had been treated
with antibiotics prior to admission to the hospital.
Prescribed antibiotics by general practitioners
were: Doxycycline (37%), Amoxicillin (21%), Amox-
icillin/Clavulanic acid (29%) and Azithromycine
(10%). Information concerning the remaining 3%
could not be retrieved. Forty-three percent of the
patients had also received a boost of oral corticos-
teroids prior to admission.
Mean hospital stay was 11.7 days and median
hospital stay was 10 days. Thirteen patients died
during their hospital stay, resulting in an in-hospital
mortality of 8%.
Seventeen patients were admitted to ICU be-
cause of progressive respiratory failure: In 15
patients failure of conservative treatment in the
first 48 h necessitated referral to the ICU; in two
patients clinical condition deteriorated after initial
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improvement. Intubation and mechanical ventila-
tion was necessary in 10 patients, four patients
received non-invasive ventilation (BiPAP) and in
three patients conservative treatment could be
continued under close supervision. Patients trans-
ferred to ICU had a longer duration of hospital stay
(P ¼ 0:005; mean 17.3 days, median 15 days). One
patient died during ICU admission (6%).
Microbiological analysis
Sputum cultures could be obtained in 142 patients
(¼ 83%). Other patients were unable to expecto-
rate sputum spontaneously during hospitalization.
Samples were considered not representative based
on microbiological criteria in 54 cases.
In 85 of the 88 representative samples (97%) a
significant bacterial growth was reported; in 61
samples (72%) there was growth of one single
species in significant concentrations, in 22 samples
(26%) there was growth of two different species in
significant concentrations and in four samples (5%)
growth of three different species in significant
concentrations was present.
The most frequently isolated species were H
influenzae (23 cases as single pathogen, 15 cases in
combination with other pathogens, overall 38/85
cases or 45%) and S. pneumoniae (nine cases as
single pathogen, 15 cases in combination with other
pathogens, overall 24/85 cases or 28%).
P. aeruginosa was isolated in 13/85 cases (15%).
Other bacteria isolated were: M. catarrhalis (three
cases as single pathogen, two cases in combination,
overall 5/85 cases or 6%), and Klebsiella pneumo-
niae (one case as single pathogen, three cases in
combination, overall 4/85 cases or 5%). In 14/85
cases (16%) NPMs were found. These data are
schematically presented in Fig. 1.
No resistant strains of S. pneumoniae to Amox-
icillin were isolated. For H. influenzae as well as for
M. catarrhalis two b-lactamase producing strains
were identified. No resistant Pseudomonas strains
were isolated in the studied population. No
significant differences were found in mean FEV1,
PaO2 and PaCO2 between the patients with and
without positive sputum culture (Table 1).
A course of antibiotics or a boost of corticoster-
oids, prescribed prior to admission, did not influ-
ence the outcome of sputum cultures. 52.4% who
had received antibiotics and 51.7% of patients who
had received a boost of corticosteroids prior to
admission had bacterial infection.
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culture (n ¼ 86)
Positive sputum
culture (n ¼ 85)
P-value
Age (years) 70.678.6 71.777.8 69.578.9 0.023
FEV1 (l, % pred) 34.6712.6 34.1713.3 35.271.9 NS
PaO2 (kPa) 7.4972.2 7.1672.0 7.8272.5 NS
PaCO2 (kPa) 6.7472.1 6.1272.1 6.6672.2 NS
Hospital stay (days) 11.778.8 10.575.6 12.9710.8 NS
Sex (M/F) 104/67 50/36 54/31 NS
Pretreatment with antibiotics (y/n) 63/108 30/56 33/52 NS
Pretreatment with corticosteroids (y/n) 73/98 29/57 31/54 NS
Chronic corticosteroids (y/n) 17/154 8/78 9/76 NS
ICU admission (y/n) 17/154 10/76 7/78 NS
Died during admission (y/n) 13/158 6/80 7/77 NS
NPM's
others
H. infl. and P.aeru















Fig. 1 Types of isolated microorganisms found during
acute exacerbations of COPD.
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No difference in duration of hospitalization could
be demonstrated between patients with and with-
out bacterial infection on admission.
In the group of patients with positive sputum
culture (n ¼ 85), 10 patients were transferred to
ICU of whom five patients were intubated for
mechanical ventilation, while in the negative
sputum culture group (n ¼ 86) seven patients were
transferred to ICU of whom four required mechan-
ical ventilation.
Admission to ICU was not related to the presence
and type of bacterial infection during exacerba-
tion.
In comparison of patients with Pseudomonas
infection to those with H. influenzae or S.
pneumoniae infections, it was demonstrated that
the former group was significantly older; other
parameters were not different between these
groups.
Lung function parameters
Based on lung function data obtained prior to
discharge from the hospital, marked airflow ob-
struction was present in the majority of the
patients: 81 patients (47%) had severe COPD 55
patients (32%) had moderate COPD and 22 patients
(13%) had mild COPD, according to ATS staging. In
12 patients, no spirometric data could be obtained
during hospital stay. Ten patients had an estab-
lished diagnosis of severe COPD based on clinical
records. In two patients, the diagnosis of COPD was
established on clinical grounds and the information
regarding medical history as obtained by their
general practitioner (Fig. 2).
The incidence of bacterial infection was signifi-
cantly related to the degree of airflow limitation
(Fig. 3): patients with severe COPD had significantly
more bacterial infections than patients classified as
moderate (P ¼ 0:015) or mild COPD (P ¼ 0:08).
However, the type of bacteria isolated was not
related to the degree of airflow limitation (Fig. 3).
Discussion
The present study confirms previous data reporting
a higher incidence of bacterial infections in
patients with a severe impairment in lung function
during hospital admissions for acute exacerbations.
However, no relationship between the type of
bacteria isolated and the degree of lung function
impairment could be demonstrated. The presence
of bacterial pathogens was found in 50% of
all admitted patients. No differences in clinical
characteristics could be demonstrated between
patients with and without isolation of bacterial
pathogens neither with the type of bacterial
pathogens. Microorganisms most frequently iso-
lated were H. influenzae (45%) and S. pneumoniae
(27%). Other pathogens isolated were P. aeruginosa
(15%), M. catarrhalis (6%) and K. pneumoniae (5%).
The presence of bacterial pathogens did not
influence the clinical outcome defined by the
length of hospital stay and the need for ICU
admission.
One of the most important findings in the present
study is the relation between the occurrence of
















p = 0.08 between severe and moderate COPD
p = 0.015 between severe and mild COPD
Fig. 2 Positive sputum cultures after stratification.




























FEV1 50-70 % FEV1 35-50 %
group 1 = H. influenza and M. catharralis
group 2 = S.pneumoniae and other Grampositive cocci
group 3 = Pseudomonas aeruginosa and other Gramnegative
micro-organisms  
group of micro-organism
Fig. 3 Distribution of groups of bacteria isolated
according to FEV1 impairment.
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limitation: patients with a lower FEV1 had a higher
incidence of bacterial infection. This is in line with
previous studies on the prevalence of bacteria in
stable COPD patients.8
However, opposite to previously reported data
we found no shift in the type of microorganism
isolated in patients with more severely compro-
mised lung function.12,13 Indeed, both Eller and
Miravitlles reported in patients with lower FEV1 a
higher incidence of Pseudomonas and Enterobac-
teriacae in their sputum. They hypothesized a
possible relationship between the decline in lung
function and occurrence of Pseudomonas and other
Gram-negative species in sputum. Our data were
even obtained in patients with more severely
compromised lung function.
The incidence of Pseudomonas infections in our
study was comparable with the data reported by
Miravitlles, but markedly lower than in the study of
Eller. Further data with more specific characteriza-
tion of the patients suffering from acute exacer-
bations will be required in order to relate these
findings to the disease condition itself. The
presence of bronchiectasis,19 nutritional status,20
as well as previous use of antibiotics21 can influence
the type and frequency of colonization of the
airways in COPD.
Remarkably, the incidence of positive sputum
cultures in half of our patient population was quite
similar to previous data.2,10,14,15 In exacerbated
outpatients, prevalence of positive bacterial cul-
tures, obtained by protected specimen brush, was
51.6%.10 In a bronchoscopic study of 54 mechani-
cally ventilated patients with acute exacerbation
of COPD, bacterial infection was found in 50% of
patients.14 In another study among mechanically
ventilated patients using protected specimen
brush, Fagon et al.22 reported distal bronchial
infection in 50% of patients during acute exacer-
bation. In a large study of 1016 in-patients with
acute exacerbation respiratory infection was found
in 47% of sputum cultures.15 Therefore, it seems a
consistent finding that bacterial infection is present
in 50% of exacerbations, in hospital as well as in
outpatient populations.
However, it remains difficult to distinguish
bacterial colonization of the lower airways from
an actual bacterial infection. In a bronchoscopic
study among 18 stable COPD patients, using
protected specimen brush samples, Cabello et al.
11 found that the distal airways were colonized
(defined as X102 cfu/ml) in 83% of COPD patients.
Quantitative cultures of BAL samples in the same
patient group remained negative in 88%, suggesting
colonization rather than infection. In another study
using protected specimen brush samples, Monso
et al.10 found positive cultures in 25% of stable
COPD patients and 52% of exacerbated COPD
patients. In the stable COPD patients, concentra-
tions of bacteria were much lower, again indicating
colonization instead of bacterial infection.
Besides differences in quantity of isolated micro-
organisms, recent studies suggest differences in the
level of inflammation in stable COPD patients as
well as during exacerbations between both condi-
tions of the presence of bacteria in the airways.
Bresser et al. 23 demonstrated that persisting
strains of H. influenzae induce a weaker inflamma-
tory response than non-persisting strains, while the
local airway inflammation in COPD patients clini-
cally infected with H. influenzae is much more
pronounced.24 Sethi et al. 25 demonstrated that
exacerbated chronic bronchitis patients with H.
influenzae and M. catharralis isolated from sputum
had increased airway inflammation when compared
to pathogen-negative exacerbations.
Other studies indicate that bacterial infection
contributes significantly to the inflammatory pro-
cess in the airways. In acute exacerbations of COPD
associated with H. influenzae infection, an increase
in sputum IL-8, TNF-a and neutrophil elastase was
found in contrast to exacerbations without bacter-
ial infection, indicating increased airway inflam-
mation in the presence of H. influenzae.26 This
inflammatory process in the airway continues
despite antibiotic and steroid therapy for exacer-
bations, as was demonstrated by unchanging
sputum cell counts during the course of an
exacerbation.27
However, the possible role of bacterial infections
in the pathogenesis of acute exacerbations is still
incompletely understood.
In the present study, the outcomes in terms of
hospital stay or subsequent need for ICU admission
were not related to the presence or the type of
bacterial infections. Our findings are in line with
the disputed role of antibiotics in the treatment of
acute exacerbations. Studies concerning the effect
of antibiotic treatment have shown either no
benefit or minimal clinical benefit from antibiotic
treatment.7 Meta-analysis of randomized con-
trolled clinical trials demonstrated a clinically
unimportant improvement in patients receiving
antibiotics.28 A recently performed meta-analysis
on antibiotic treatment in acute exacerbations
concluded that patients with more severe exacer-
bations are more likely to benefit from antibiotic
treatment.29
A recent study in exacerbated outpatients by
Adams et al. 9 demonstrated lower relapse rates
in outpatients treated with antibiotics, compared
to patients untreated with antibiotics, but even
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higher relapse rates in patients treated with
Amoxicillin. These results indicate that type of
antibiotics used to treat acute exacerbations have
an impact on the failure rate.
In this respect, it is interesting to compare
exacerbations of COPD to ventilator-associated
pneumonia (VAP), a combination of clinical para-
meters in mechanically ventilated patients, that is
presumed to be caused by bacteria and treated
with antibiotics. In a recent bronchoscopic study
among VAP patients, using protected specimen
brush and BAL samples, bacterial infection was
not proven in 43% of patients and withholding
antibiotics in these patients had no effect on
outcomes.30 In another bronchoscopic study of
VAP patients, the bacterial burden was not corre-
lated with inflammatory mediators or with patient
outcome.31
Some limitations of the present study need
further discussion. Spontaneously expectorated
sputum was used for microbiological sampling, in
contrast to for example induced sputum or
bronchoscopic sampling. The suitability of sputum
samples to analyze bacterial infection is a matter
of debate. Recently, a good concordance between
the results of two sampling methods, valid sputum
samples and quantitative protected specimen
brush, was shown.32 At present, especially in
patients with severe COPD, spontaneously expec-
torated sputum seems a clinically reliable method
to assess the presence and type of bacterial
infections when other methods have to be avoided.
The present study has not included data on viral
infections or infections with atypical organisms like
Chlamydia and Mycoplasma. The presence of viral
infection and Mycoplasma and Chlamydia during
COPD exacerbations has been evaluated in differ-
ent studies. In an outpatient population of mild-to-
moderate COPD exacerbations, incidence of Chla-
mydia pneumoniae was found to be 4%.33 In a study
of mechanically ventilated patients with acute
exacerbations of COPD, an incidence of C. pneu-
moniae of 18% was found.14 The same study found
no evidence for Mycoplasma pneumoniae infection
and an incidence of 16% for respiratory viruses. In a
Turkish study of outpatients with acute exacerba-
tion, incidence of C. pneumoniae was 22% and M.
pneumoniae incidence was 6%.34
So far, most studies concerning respiratory
pathogens have been performed in either out-
patient populations with mild exacerbation, or
mechanically ventilated patients with severe ex-
acerbations in an ICU setting. Neither of these
populations can be considered representative for
the majority of admissions for COPD exacerbations
in a clinical setting, as in the present study.
Therefore, the role of these non-bacterial patho-
gens in the pathogenesis of COPD exacerbations
needs further exploration.
The present study indicates that the role of
bacterial infections in the complex pathogenesis of
COPD exacerbations as well as its clinical signifi-
cance needs further evaluation in the near future
and cannot be restricted to the limited discussion
of the role of antibiotic treatment in the manage-
ment of these acute events in the clinical course of
patients with acute exacerbations. Especially, the
role of bacterial infections in relation to the local
and systemic inflammatory response has to be
unraveled. The impact of acute exacerbations on
the socio-economic burden of this disease as well as
on the health status of the individual patient
urgently needs to prioritize acute exacerbations
in order to better understand the natural course of
COPD.
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